Unhappy With GDUFA II? Note It For GDUFA III, FDA Says
Executive Summary
US agency says it is implementing generic drug user fee program as outlined in commitment letter and any changes should be discussed at negotiations for the 2022 renewal.
You may also be interested in...
Generic Sample Access Process For REMS-Protected Brands Now Includes Agency Timeline
US FDA has 120 days to review generic sponsors’ requests for letters to help them obtain product samples, but will not send them to the reference product company.
Generic Sample Access Process For REMS-Protected Brands Now Includes Agency Timeline
US FDA has 120 days to review generic sponsors’ requests for letters to help them obtain product samples, but will not send them to the reference product company.
GDUFA III: How Much Of A Fee Increase Can Industry Stomach?
Amid questions about generic industry market dynamics, the user fee renewal could focus on limiting increases in US FDA collections.